Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition-Reference-Cited by-同舟云学术

Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition

Published:2019-05 Issue: Volume:135 Page:167-181
ISSN:0891-5849
Container-title:Free Radical Biology and Medicine
language:en
Short-container-title:Free Radical Biology and Medicine

Author:

Cruz-Bermúdez Alberto,Laza-Briviesca Raquel,Vicente-Blanco Ramiro J.,García-Grande Aránzazu,Coronado Maria José,Laine-Menéndez Sara,Palacios-Zambrano Sara,Moreno-Villa M. Rocío,Ruiz-Valdepeñas Asunción Martin,Lendinez Cristina,Romero Atocha,Franco Fernando,Calvo Virginia,Alfaro Cristina,Acosta Paloma Martin,Salas Clara,Garcia José Miguel,Provencio Mariano

Funder

Instituto de Salud Carlos III

Comunidad Autónoma de Madrid

Publisher

Elsevier BV

Subject

Physiology (medical),Biochemistry

Reference48 articles.

1. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Vansteenkiste;Ann. Oncol.,2013

2. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Novello;Ann. Oncol.,2016

3. Targeted therapies for advanced non-small-cell lung cancer: current status and future implications;Custodio;Cancer Treat Rev.,2012

4. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges;Tartari;Cancer Treat Rev.,2016

5. Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer;Fennell;Cancer TreatCancer Treat Rev. Rev.,2016

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GLIDR-mediated regulation of tumor malignancy and cisplatin resistance in non-small cell lung cancer via the miR-342-5p/PPARGC1A axis;BMC Cancer;2024-09-10

2. Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives;Journal of Hematology & Oncology;2024-08-16

3. A pan-cancer cuproptosis signature predicting immunotherapy response and prognosis;Heliyon;2024-08

4. LncRNA SH3PXD2A-AS1 facilitates cisplatin resistance in non-small cell lung cancer by regulating FOXM1 succinylation;BMC Cancer;2024-07-17

5. Pleiotropic Regulation of PGC-1α in Tumor Initiation and Progression;Antioxidants & Redox Signaling;2024-07-10